Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.40 |
| ▸ | CES2 | O00748 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28027383 | 0.92 | CES2 (0.42) | CES1CES2ALDH1A1LMNAMEN1 | |
| SCHEMBL3917215 | 0.86 | CES1 (0.32) | CES1CES2 | |
| SCHEMBL743494 | 0.77 | — | — | |
| SCHEMBL10686722 | 0.74 | CES2 (0.48) | CES1CES2ALDH1A1TP53CA1 | |
| SCHEMBL15910517 | 0.73 | — | — | |
| SCHEMBL16194365 | 0.72 | — | — | |
| SCHEMBL11126902 | 0.72 | CES1 (0.40) | CES1CES2ALDH1A1TP53CA1 | |
| SCHEMBL7116034 | 0.70 | CA1 (0.43) | CES1CES2ALDH1A1TP53CA1 | |
| SCHEMBL25595554 | 0.69 | LMNA (0.39) | CES1CES2ALDH1A1LMNAMEN1 | |
| SCHEMBL18613979 | 0.69 | CES2 (0.46) | CES1CES2ALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718016-B1 | NEW COMPLEXES OF RUTHENIUM, METHOD FOR THEIR PREPARATION, AND THEIR APPLICATION IN OLEFIN METATHESIS REACTIONS | UMICORE AG & CO KG (DE) | 2019-08-14 | — | — | EP | disclosed |
| EP-2718016-A1 | NEW COMPLEXES OF RUTHENIUM, METHOD FOR THEIR PREPARATION, AND THEIR APPLICATION IN OLEFIN METATHESIS REACTIONS | Umicore AG & Co. KG (DE) | 2014-04-16 | — | — | EP | disclosed |
| EP-2644284-A1 | Group 2 Imidazolate Formulations for Direct Liquid Injection | Air Products and Chemicals, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012168183-A1 | NEW COMPLEXES OF RUTHENIUM, METHOD FOR THEIR PREPARATION, AND THEIR APPLICATION IN OLEFIN METATHESIS REACTIONS | UMICORE AG & CO. KG (DE) | 2012-12-13 | — | — | WO | disclosed |
| EP-1928243-A2 | THIAZOLES USED AS FUNGICIDES | Bayer CropScience AG (DE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007033780-A2 | THIAZOLES USED AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2007-03-29 | — | — | WO | disclosed |
| US-7030135-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-04-18 | — | — | US | disclosed |
| WO-2005093476-A1 | TRANSPARENT FILM AND OPTICAL COMPENSATORY FILM, POLARIZING PLATE AND LIQUID-CRYSTAL DISPLAY DEVICE EMPLOYING IT | FUJI PHOTO FILM CO., LTD. (JP) | 2005-10-06 | — | — | WO | disclosed |
| US-6913903-B2 | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same | NOBEX CORPORATION (US) | 2005-07-05 | — | — | US | disclosed |
| US-20030199501-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199501-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | CES1 21/4885CES2 509/4885ALDH1A1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.